Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649084 | 0.84 | MAPT (0.40) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL13755083 | 0.82 | MAPT (0.42) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL16122424 | 0.82 | ALDH1A1 (0.50) | MAPTLMNACYP2C9ALDH1A1KDM4E | |
| SCHEMBL14783801 | 0.81 | KDM4E (0.44) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL14782648 | 0.81 | MAPT (0.41) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL15819818 | 0.81 | ALDH1A1 (0.44) | MAPTLMNACYP2C9L3MBTL1ALDH1A1 | |
| SCHEMBL31124656 | 0.80 | MAPT (0.53) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL7064467 | 0.80 | MAPT (0.53) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL31432707 | 0.78 | LMNA (0.39) | MAPTLMNACYP2C9NPC1RAB9A | |
| SCHEMBL29170430 | 0.78 | ENPP2 (0.40) | MAPTLMNACYP2C9NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116390-A1 | PYRIMIDINE-2(1H)-ONE-FUSED BICYCLIC COMPOUND HAVING MAT2A INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023116390-A1 | PYRIMIDINE-2(1H)-ONE-FUSED BICYCLIC COMPOUND HAVING MAT2A INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8357716-B2 | Pyrazole derivatives used as CCR4 receptor antagonists | GLAXO GROUP LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8304446-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-6680402-B2 | SUCH AS N-PHENYLACETYL-2-DIFLUOROMETHOXY-6-FLUOROBENZAMIDE-O-CYCLOPROPYLMETHYL OXIME | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-20 | — | — | US | disclosed |
| US-20030120085-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | EICKEN KARL (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6509501-B2 | Agriculture | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-21 | — | — | US | disclosed |
| EP-1017670-B1 | BENZAMIDOXIM DERIVATIVES, INTERMEDIATE PRODUCTS AND METHODS FOR PREPARING AND USING THEM AS FUNGICIDES | BASF AG (DE) | 2002-11-27 | — | — | EP | disclosed |
| EP-1254102-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20020133025-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | EICKEN KARL (DE) | 2002-09-19 | — | — | US | disclosed |
| US-6420605-B1 | DIFLUOROMETHYL ETHERS OF BENZAMIDOXIME COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-16 | — | — | US | disclosed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133025-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | CBR1, CBR3, CYP1B1 | MAPT 4588/4885LMNA 1844/4885CYP2C9 42/4885 |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | MAPT 1942/4885LMNA 4549/4885CYP2C9 330/4885 |
| US-20130030031-A1 | Novel Compounds | CYP3A4, CYP3A43, ABCG2 | MAPT 323/4885LMNA 1612/4885CYP2C9 10/4885 |
| US-20030120085-A1 | Novel benzamidoxime derivatives, intermediates and processes for their preparation, and their use as fungicides | CBR1, CBR3, CYP1B1 | MAPT 4588/4885LMNA 1844/4885CYP2C9 42/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | MAPT 323/4885LMNA 1612/4885CYP2C9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.